Scrip Asks…What Does 2023 Hold For Biopharma? Part 9: The Natural Environment
Efficiency And Collaboration Needed To Cut Sector Emissions
Improving human health is the raison d’etre of the biopharma sector. But what can the industry do to safeguard and improve the health of Planet Earth? Executives shared their thoughts with Scrip.
You may also be interested in...
Health care companies making carbon neutrality claims must tread a careful line while ensuring full accountability. CMS Vienna partner Gabriela Staber points to some of the risks businesses should be aware of when making sustainability claims.
Medicines for Europe, along with EFPIA and the AESGP, say that the ‘polluter pays’ principle behind proposed new European rules on wastewater treatment would saddle pharmaceutical manufacturers with costs that “jeopardize patient access.”
The France-headquartered company has brought forward its carbon neutral goal, making it one of the sector’s most proactive companies.